|
In the United States, 1.8% of the population has been infected with the Hepatitis C virus (HCV) and up to 10,000 die from HCV related chronic liver disease each year. Current treatment options aimed to eradicate HCV liver disease are all Interferon based (+/- Ribavirin). In the past, studies have used highly selected patient groups to determine the sustained response rate of Interferon therapy. However, the potential impact on viral eradication with Interferon therapy in a metropolitan Liver Disease Clinic's Hepatitis C patient population is less well known.
|
